• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 85 of 100
Martin Shkreli, CEO Reviled for Drug Price Gouging, Arrested on Securities Fraud Charges
HealthMartin Shkreli’s Twitter Account Hacked
By Reuters and Aaron TaskDecember 20, 2015
Martin Shkreli arrested
HealthMartin Shkreli’s Arrest Halts Leukemia Drug Trial
By Michal AddadyDecember 20, 2015
Martin Shkreli Says Securities Fraud Charges Are ‘Baseless’
LeadershipMartin Shkreli Says Securities Fraud Charges Are ‘Baseless’
By ReutersDecember 19, 2015
Inside of a Gilead Sciences Lab
FinanceIsis Pharmaceuticals Changes Its Name After Terrorists Attack Stock Price
By Jen WiecznerDecember 18, 2015
US-CRIME-JUSTICE-SHKRELI
HealthTuring Replaces Martin Shkreli with Interim CEO
By Laura LorenzettiDecember 18, 2015
Martin Shkreli, CEO Reviled for Drug Price Gouging, Arrested on Securities Fraud Charges
LeadershipMartin Shkreli’s 15 Minutes Are Up
By Geoff ColvinDecember 18, 2015
Turing Pharmaceutical CEO Martin Shkreli Arrested For Securities Fraud
HealthHow Pharmacies Are Dealing with Daraprim After Martin Shkreli’s Arrest
By ReutersDecember 18, 2015
BRITAIN-PHARMACEUTICAL-GSK
HealthEurope’s Pharma Sector Is Finishing 2015 With a Deal Flurry
By Geoffrey SmithDecember 18, 2015
BRITAIN-PHARMA-BUSINESS-ASTRAZENECA
FinanceThe Year’s Best VC Deal Was for a Company You’ve Never Heard Of
By Dan PrimackDecember 17, 2015
BRITAIN-PHARMA-BUSINESS-ASTRAZENECA
HealthAstraZeneca Wants a Stake in This Biotech Firm for a Cancer Cure
By ReutersDecember 17, 2015
Views Of A CVS Caremark Corp. Store Ahead Of Earns
RetailCVS Slams Walgreens-Valeant Distribution Deal
By Phil WahbaDecember 16, 2015
MSMB Capital Management CIO Martin Shkreli
LeadershipYet Another Reason to Hate Martin Shkreli
By Daniel RobertsDecember 16, 2015
468673318
HealthHere’s How Your Health Care Is Going to Change in 2016
By Laura LorenzettiDecember 16, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceCongressman Calls Out Valeant’s ‘Lack of Transparency’
By Laura LorenzettiDecember 16, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
RetailWalgreens Comes to Valeant’s Help
By Phil WahbaDecember 15, 2015
1...
  • 83
  • 84
  • 85
  • 86
  • 87
...100
Most Popular
Economy
The U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combinedplaceholder alt text
By Fortune EditorsApril 9, 2026
AI
A Meta employee created a dashboard so coworkers can compete to be the company's No. 1 AI token user—and Zuckerberg doesn't even rank in the top 250placeholder alt text
By Fortune EditorsApril 9, 2026
Investing
Mark Cuban admits he made a mistake letting go of the Mavericks: 'I don't regret selling. I regret who I sold to'placeholder alt text
By Fortune EditorsApril 9, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.